Cellular and molecular aspects of contractile dysfunction in heart failure

Cardiovascular Research

Volumn 39, Issue 2, 1998, Pages 267-275

  Mittmann, C ^a   Eschenhagen, T ^a   Scholz, H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACTILE PROTEIN;

CALCIUM HOMEOSTASIS; EDITORIAL; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; INOTROPISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

CALCIUM; CARDIOTONIC AGENTS; CONTRACTILE PROTEINS; DIASTOLE; GENE EXPRESSION; HEART; HEART FAILURE, CONGESTIVE; HOMEOSTASIS; HUMANS; MYOCARDIAL CONTRACTION; MYOCARDIUM; SIGNAL TRANSDUCTION; SYSTOLE;

EID: 0032145260     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(98)00139-4     Document Type: Editorial

References (101)

1. [1] Dalla-Volta S, Razzolini R, Scognamiglio R, Rubino A, Chioin R. Myocardial function in heart failure. Cardiology 1988;75(Suppl I):8-18.
2. [2] Glower DD, Spratt JA, Snow ND. Linearity of the Frank-Starling relationship in the intact heart: the concept of preload recruitable stroke work. Circulation 1985 ;71:994-1009.
3. [3] Jacob R, Kissling G. Ventricular pressure-volume relations as the primary basis for evaluation of cardiac mechanics. Return to Frank's diagram. Basic Res Cardiol 1989;84:227-246.
4. [4] Opie LH. Regulation of myocardial contractility. J Cardiovasc Pharmacol 1995;26(Suppl 1):S1-S9.
5. [5] Mercadier JJ, Bouveret P, Gorza L et al. Myosin isoenzymes in normal and hypertrophied ventricular myocardium. Circ Res 1983;53:52-62.
6. [6] Pagani ED, Alousi AA, Grant AM, Older TM, Dziuban SW, Allen PD. Changes in myofibrillar content and Mg-ATPase activity in ventricular tissues from patients with heart failure caused by coronary artery disease, cardiomyopathy, or mitral valve insufficiency. Circ Res 1988;63:380-385.
7. [7] Hirzel HO, Tuchschmid CR, Schneider J, Krayenbuehl HP, Schaub MC. Relationship between myosin isoenzyme composition, hemodynamics, and myocardial structure in various forms of human cardiac hypertrophy. Circ Res 1985;57:729-740.
8. [8] Schier JJ, Adelstein RS. Structural and enzymatic comparison of human cardiac muscle myosins isolated from infants, adults, and patients with hypertrophic cardiomyopathy. J Clin Invest 1982;69:816-825.
9. [9] Hajjar RJ, Gwathmey JK. Cross-bridge dynamics in human ventricular myocardium. Regulation of contractility in the failing heart. Circulation 1992;86:1819-1826.
10. [10] Hasenfuss G, Mulieri LA, Leavitt BJ, Allen PD, Haeberle JR, Alpert NA. Alteration of contractile function and excitation-contraction coupling in dilated card iomyopathy. Circ Res 1992;70:1225-1232.
11. [11] Hammond EH, Menlove RL, Anderson JL. Predictive value of immunofluorescence and electron microscopic evaluation of endomyocardial biopsies in the diagnosis and prognosis of myocarditis and idiopathic dilated cardiomyopathy. Am Heart J 1987;114:1055-1065.
12. [12] Anderson PEW, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in humans. Circ Res 1991 ;69:1226-1233.
13. [13] Anderson PAW, Malouf NN, Oakeley AE, Pagani ED, Allen PD. Troponin T isoform expression in the normal and failing human left ventricle: a correlation with myofibrillar ATPase activity. Basic Res Cardiol 1991;46:117-127.
14. [14] Wolff MR, Buck SH, Stoker SW, Graeser ML, Mentzer RM. Myofibrillar calcium sensitivity of isometric tension is increased in human dilated cardiomyopathies. Role of altered β-adrenergically mediated protein phosphorylation. J Clin Invest 1996;98:167-176.
15. [15] Sutsch G, Brunner UT, von Schulthess C et al. Hemodynamic performance and myosin light chain-1 expression of the hypertrophied left ventricle in aortic valve disease before and aftervalve replacement. Circ Res 1992;70:035-1043.
16. [16] Margossian SS, White HD, Caulfield JB, Norton P, Taylor S, Slayter HS. Light chain 2 profile and activity of human ventricular myosin during dilated cardiomyopathy. Identification of a causal agent for impaired myocardial function. Circulation 1992;85:1720-1733.
17. [17] Bodor GS, Oakeley AE, Allen PD, Crimmins DL, Ladeson JH, Anderson PAW. Troponin I phosphorylation in the normal and failing adult human heart. Circulation 1997;96:1495-1500.
18. [18] Bartel S, Stein B, Eschenhagen T et al. Protein phosphorylation in isolated trabeculae from nonfailing and failing human hearts. Mol Cell Biochem 1996;157:171-179.
19. [19] Bers DM. Myofilaments: The end effector of EC coupling. In: Bers DM, Excitation-contraction coupling and cardiac contractile force. Developments in cardiovascular medicine, Vol. 122. Dordrecht, Boston, London: Kluwer Academic Publishers, 1991: 17-32.
20. [20] Solaro RJ. Troponin, C-troponin I interactions and molecular signalling in cardiac myofilaments. Adv Exp Med Biol 1995;382:109-115.
21. [21] Schwinger RHG, Bohm M, Koch A et al. The failing human heart is unable to use the Frank-Starling Mechanism. Circ Res 1994;74:959-969.
22. [22] Vahl CF, Timek T, Bonz A et al. Myocardial length-force relationship in end stage dilated cardiomyopathy and normal human myocardium: Analysis of intact and skinned left ventricular trabeculae obtained during 11 heart transplantations. Basic Res Cardiol 1997;92:261-270.
23. 2+ in intact and skinned trabeculae from control and myopathic human hearts. J Clin Invest 1988;82:1578-1584.
24. [24] Gwathmey JK, Slawsky MT, Hajjar RJ, Griggs GM, Morgan JP. Role of intracellular calcium handling in force-interval relationships of human ventricular myocardium. J Clin Invest 1990;85:1599-1613.
25. [25] Wankerl M, Bohm M, Morano I, Ruegg JC, Eichhorn M, Erdmann E. Calcium sensitivity and myosin light chain pattern of atrial and ventricular skinned cardiac fibers from patients with various kinds of cardiac disease. J Mol Cell Cardiol 1990;22:1425-1438.
26. 2+ release activity of the sarcoplasmic reticulum in dilated card iomyopathy. Circulation 1992;85:518-525.
27. [27] Gwathmey JK, Copelas L, MacKinnon R et al. Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 1987;61:70-76.
28. [28] Beuckelmann DJ, Nabauer M, Erdmann E. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. Circulation 1992;85:1046-1055.
29. [29] Vahl CF, Bonz A, Timek T, Hagl S. Intracellular calcium transient of working human myocardium of seven patients transplanted for congestive heart failure. Circ Res 1994;74:952-958.
30. [30] Pieske B, Kretschmann B, Meyer M et al. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cadiomyopathy. Circulation 1995 ;92:1169-1178.
31. [31] Rasmussen RP, Minobe W, Bristow M. Calcium antagonist binding sites in failing and nonfailing human ventricular myocardium. Biochem Pharmacol 1990;39:691-696.
32. 2+ channel) and calsequestrin genes in the myocardium of patients with end-stage heart failure. J Clin Invest 1992;90:927-935.
33. [33] Schumacher C, Konigs B, Sigmund M et al. The ryanodine binding sarcoplasmic reticulum calcium release channel in nonfailing and in failing human myocardium. Naunyn-Schmiedeberg's Arch Pharmacol 1995;353:80-85.
34. [34] Gómez AM, Valdivia HH, Cheng H et al. Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure. Science 1997;276:800-806.
35. [35] Limas CJ, Olivari MT, Goldenberg IF, Levine TB, Benditt DG, Simon A. Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 1987;21:601-605.
36. 2+ ATPase in failing and nonfailing human myocardium. Circ Res 1994;75:434-442.
37. 2+-and ATPase-cycling imbalances in end-stage dilated and ischemic cardiomyopathies. Cardiovasc Res 1995;30:394-404.
38. [38] Flesch M, Schwinger RHG, Schnabel P et al. Sarcoplasmic reticulum Ca ATPase and phospholamban mRNA and protein levels in end-stage heart failure due to ischemic or dilated cardiomyopathy. J Mol Med 1996;74:321-332.
39. 2+ uptake by cardiac sarcoplasmic reticulum from patients with idiopathic dilated cardiomyopathy. Circ Res 1989;65:1141-1144.
40. 2∼-ATPase in failing and nonfailing human hearts. Cardiovasc Res 1996;31:625-632.
41. 2+ exchanger in failing human myocardium. Circulation 1996;94:992-1002.
42. 2+ exchanger in end stage human heart failure. Circ Res 1994;75:443-453.
43. [43] Hasenfuss G, Meyer M, Schillinger W, Preuss M, Pieske B, Just H. Calcium handling proteins in the failing human heart. Basic Res Cardiol 1997;92(Suppl I):87-93.
44. [44] Steinfath M, Geertz B, Schmitz W et al. Distinct down-regulation of cardiac β1-and β2-adrenoceptors in different human heart diseases. Naunyn-Schmiedeberg's Arch Pharmacol 1991;343:217-220.
45. [45] Brodde OE. β1-and β2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 1991;43:203-242.
46. [46] Bristow MR, Hersheberger RE, Port JD, Minobe W, Rasmussen R. β1-and β2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharmacol 1989;35:295-303.
47. [47] Danielsen W, v der Leyen H, Meyer W et al. Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 1989;14:171-173.
48. [48] Ungerer M, Bohm M, Elce JS, Erdmann E, Lohse MJ. Altered expression of β-adrenergic receptor kinase and β1-adrenergic receptors in the failing human heart. Circulation 1993;87:454-463.
49. [49] Feldman AM, Gates AE, Veazey WB et al. Increase in the 40,000-mol wt pertussis toxin substrate (G-protein) in the failing human heart. J Clin Invest 1988;82:189-197.
50. [50] Neumann J, Schmitz W, Scholz H, von Meyerinck L, Döring V, Kalmár P. Increase of myocardial Gi-proteins in human heart failure. Lancel 1988;II:936-937.
51. [51] Bohm M, Gierschik P, Jakobs KH et al. Increase of Giα in human hearts with dilated but not ischémic cardiomyopathy. Circulation 1990;82:1249-1265.
52. [52] Eschenhagen T, Mende U, Nose M et al. Increased messenger RNA level of the inhibitory G-protein a-subunit Gkx-2 in human end-slage heart failure. Circ Res 1992;70:688-696.
53. [53] Eschenhagen T. G proteins and the heart. Cell Biol Internal 1993;17:723-749.
54. [54] Komamura K, Shannon RP, Ihara T et al. Exhaustion of Frank-Starling mechanism in conscious dogs with heart failure. Am J Physiol 1993;265:H1113-H1119.
55. [55] Holubarsch C, Ruf T, Goldstein DJ et al. Existence of the Frank-Starling mechanism in the failing human heart. Investigations on the organ, tissue, and sarcomere levels. Circulation 1996;94:683-689.
56. [56] Weil J, Eschenhagen T, Hirt S et al. Preserved Frank-Starling mechanism in terminally failing human hearts. Cardiovasc Res 1998;37:451-458.
57. [57] Ross Jr. J, Dean F, Shigetake S. Preload, afterload, and the role of afterload mismatch in the adescending limb of cardiac fundtion. Eur J Cardiol 1976;4(Suppl):77-86.
58. [58] Kitzman DW, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991;17:1065-1072.
59. [59] Bowditch HP. Uber die Eigenthumlichkeiten der Reizbarkeit, welche die Herzmuskelfasern des Herzens zeigen. Verb K Sachs Ges Wiss Leipzig 1871;23:652-689.
60. [60] Sheu SS. Cytosolic sodium concentration regulates contractility of cardiac muscle. Basic Res Cardiol 1988;24:35-45.
61. [61] Piot C, Lemaire S, Albat B, Seguin J, Nargeot J, Richard S. High frequency-induced upregulation of human cardiac calcium currents. Circulation 1996;93:120-128.
62. [62] Trautwein W, Hescheler J. Regulation of cardiac L-type calcium current by phosphorylation and G-proteins. Annu Rev Physiol 1990;52:257-274.
63. [63] Gleason WL, Braunwald E. Studies on the first derivative of the ventricular pressure pulse in man. J Clin Invest 1962;41:80-91.
64. [64] McKay RG, Aroesty JM, Heller GV et al. Left ventricular pressure-volume diagrams and end-systolic pressure-volume relations in human beings. J Am Coll Cardiol 1984;3:301-312.
65. [65] Aroesty JM, McKay RG, Heller GV, Royal HD, Als A, Grossman W. Simultaneous assessment of left ventricular systolic and diastolic dysfunction during pacing-induced ischemia. Circulation 1985;71:889-900.
66. [66] Grossman W, McLaurin L, Ellis R. Alterations in left ventricular relaxation and diastolic compliance in congestive cardiomyopathy. Cardiovasc Res 1979;13:514-522.
67. [67] Feldman MD, Alderman JD, Aroesty JM et al. Depression of systolic and diastolic myocardial reserve during atrial pacing tachycardia in patients with dilated cardiomyopathy. J Clin Invest 1988;82:1661-1669.
68. [68] Buckley NM, Penefsky ZJ, Litwak RS. Comparative force-frequency relationships in human and other mammalian ventricular myocardium. Pflugers Arch Gesamte Physiol Menschen Tiere 1972;332:259-270.
69. [69] Penefsky ZJ, Buckley NM, Litwack RS. Effects of temperature and calcium on force-frequency relationships in mammalian ventricular myocardium. Pflugers Arch Gesamte Physiol Menschen Tiere 1972;332:271-282.
70. [70] Feldman MD, Gwathmey JK, Phillips P et al. Reversal of the force-frequency relationship in working myocardium from patients with end-stage heart failure. J Appl Cardiol 1988;3:273-283.
71. [71] Mulieri LA, Hasenfuss G, Leavitt B, Allen P, Alpert NR. Altered myocardial force-frequency relation in human heart failure. Circulation 1992;85:1743-1750.
72. [72] Davies CH, Davia BS, Bennet JG, Pepper JR, Poole-Wilson PA, Harding SE. Reduced contraction and altered frequency response of isolated ventricular myocytes from patients with heart failure. Circulation 1995;92:2540-2549.
73. [73] Phillips PJ, Gwathmey JK, Feldman MD, Schoen FJ, Grossman W, Morgan JP. Post-extrasystolic potentiation and the force-frequency relationship: differential augmentation of myocardial contractility in working myocardium from patients with end-stage heart failure. J Mol Cell Cardiol 1990;22:99-110.
74. [74] Böhm M, La Rosée K, Schmidt U, Schwinger RHG, Erdmann E. Force-frequency relationship and inotropic stimulation in the non-failing and failing human myocardium: implications for the medical treatment of heart failure. Clin Invest 1992;70:421-425.
75. [75] Mulieri LA, Leavitt BJ, Martin BJ, Haeberle JR, Alpert NR. Myocardial force-frequency defect in mitral regurgitation heart failure is reversed by forskolin. Circulation 1993;88:2700-2704.
76. [76] Schwinger RHG, Böhm M, Muller-Ehmsen J et al. Effect of inotropic stimulation on the negative force-frequency relationship in the failing heart. Circulation 1993;88:2267-2276.
77. [77] Kohl C, Schmitz W, Scholz H et al. Evidence for α1-adrenoceptor-mediated increase of inositol triphosphate in the human heart. J Cardiovasc Pharmacol 1989;13:324-327.
78. [78] Kohl C, Schmitz W, Scholz H, Scholz J. Evidence for the existence of inositol tetrakisphosphale in mammalian heart. Effect of α1-adrenoceplor stimulation. Circ Res 1990;66:580-583.
79. [79] Scholz H, Eschenhagen T, Mende U, Neumann J, Schmitz W, Steinfath M. Possible mechanisms of the positive inotropic effect of α-adrenergic receptor stimulation in the heart. In: Fujiwara M, Sugimoto T, Kogure K, editors. α-Adrenoceplors: Signal transduction, ionic channels and effector organs. Amsterdam-Hong Kong-Princeton-Sidney-Tokyo: Excerpta Medica. 1992:101-111.
80. [80] Terzic A, Pucéat M, Vassort G, Vogel SM. Cardiac α1-adrenoceptors: an overview. Pharmacol Rev 1993;45:147-175.
81. [81] Brislow MR, Ginsburg R, Minobe W et al. Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. New Engl J Med 1982;307:205-211.
82. [82] Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR. Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor down-regulation and subsensitivity to agonist response. Circulation 1986;74:1290-1302.
83. [83] Colucci WS, Parker JD. Effects of β-adrenergic agents on systolic and diastolic myocardial function in patients with and without heart failure. J Cardiovasc Pharmacol 1989;14(suppl 5):528-537.
84. [84] Steinfath M, Danielsen W, v der Leyen H et al. Reduced α1-and β2-adrenoceptor-mediated positive inotropic effects in human end-stage heart failure. Br J Pharmacol 1992;105:463-469.
85. [85] v d Leyen H, Mende U, Meyer W et al. Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase Ill inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn-Schmiedeberg's Arch Pharmacol 1991;344:90-100.
86. [86] Bethke T, Klimkiewicz A, Kohl C et al. Effects of isomazole on force of contraction and phosphodiesterase isoenzymes I-IV in nonfailing and failing human hearts. J Cardiovasc Pharmacol 1991;18:386-397.
87. [87] Feldman MD, Copelas L, Gwathmey JK. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure. Circulation 1987;75:331-339.
88. [88] Schmitz W, Scholz H, Erdmann E. Effects of alpha-and beta-adrenergic agonists, phosphodiesterase inhibitors and adenosine in isolated human heart muscle preparations. Trends Pharmacol Sci 1987;8:447-450.
89. [89] Schwinger RHG, Böhm M, Mittmann C, Erdmann E. Evidence for a sustained effectiveness of sodium-channel activators in failing human myocardium. J Mol Cell Cardiol 1991;23:461-471.
90. [90] Schwinger RHG, Böhm M, Erdmann E. Effectivenes of cardiac glycosides in human myocardium with and without 'downregulated' β-adrenoceptors. J Cardiovasc Pharmacol 1990;15:692-697.
91. [91] Norgaard A, Bjerregaard P, Baandrup U, Kjeldsen K, Reske-Nielsen E, Thomsen PE. The concentration of the Na,K-pump in skeletal and heart muscle in congestive heart failure. Int J Cardiol 1990;26:185-192.
92. [92] Shamray OI, Grupp IL, Grupp G et al. Characterisation of Na/K-ATPase, its isoforms, and the inotropic response to ouabain in isolated failing human hearts. Cardiovasc Res 1993;27:2229-2237.
93. [93] Skomedal T, Borthne K, Aass H, Geiran O, Osnes JB. Comparison between alpha-I adrenoceptor-mediated and beta adrenoceptor-mediated inotropic components elicited by norepinephrine in failing human ventricular muscle. J Pharmacol Exp Ther 1997;280:721-729.
94. [94] Bristow MR, Minobe W, Rasmussen R, Hershberger RE, Hoffman BB. Alpha-I adrenergic receptors in nonfailing and failing human heart. J Pharmacol Exp Ther 1988;247:1039-1045.
95. [95] Böhm M, Diet F, Feiler G, Kemkes B, Erdmann E. α-adrenoceptors and α-adrenoceptor-mediated positive inotropic effects in failing human myocardium. J Cardiovasc Pharmacol 1988;12:357-361.
96. ++ sensitizers impair cardiac relaxation in failing human myocardium. J Pharmacol Exp Ther 1997;280:247-254.
97. [97] Brutsaert DL, Sys SU. Relaxation and diastole of the heart. Physiol Rev 1989;69:1228-1315.
98. [98] Weber KT, Brilla CG, Janicki JS. Myocardial fibrosis: Functional significance and regulatory factors. Cardiovasc Res 1993;27:341-348.
99. [99] Brutsaert DL, Claes VA, de Clerk NM. Relaxation of mammalian single cardiac cells after pretreatment with the detergent Brij-58. J Physiol 1978;283:481-491.
100. [100] Brutsaert DL, de Clerk NM, Goethals MA, Housmans PR. Relaxation of ventricular cardiac muscle. J Physiol 1978;283:469-480.
101. [101] Chuck LH, Goethals MA, Parmley WW, Brutsaert DL. Load insensitive relaxation caused by hypoxia in mammalian cardiac muscle. Circ Res 1981;48:797-803.